This proposal for a European Cancer Patient Digital Centre (ECPDC) Information Portal, EU-CIP, addresses the information needs of cancer patients, survivors, relatives, and caregivers. EU-CIP aims to create a patient-centric cancer information portal that improves health literacy, empowers patients, and reduces inequalities in access to cancer care information across Europe. The EU-CIP primary goal is to improve quality of life and enhance cancer patient care by improving access to general and personalized knowledge, delivering comprehensive information on cancer prevention, early detection, diagnosis, and treatment options including risks, side effects and late effects as well as information on rehabilitation and management of recurrence and palliative care. EU-CIP will prioritise high-incidence cancers, those with poor prognosis, and paediatric cancers. A Common Library of Contents available to all Member States will be created and EU-CIP nodes will be deployed in 10 Member States. The Library of Contents will use information from evidence-based sources such as the Knowledge Centre on Cancer and the European Cancer Information Service, existing Cancer Information Portals, and European guidelines. A governance framework for scalable content creation and review processes supported by AI tooling will be established. The consortium partners, including several patient organisations, will ensure that the patients’ view is reflected in the content review and technology usability aspects. The EU-CIP Central and local nodes will be built in a modular fashion to allow integration with existing electronic health infrastructures. To align with the EU Cancer Mission goal to improve lives through prevention, EU-CIP will raise awareness about the Mission and Europe’s Beating Cancer Plan. Alignment with the Mission’s overall plans will be realized through collaboration with the EU funded projects of the related 01-01/01-02 calls.

Relapse of acute lymphoblastic leukemia (ALL) remains a leading cause of mortality in childhood cancer. IntReALL 2020 will conduct randomized and historically controlled trials in children with relapsed B-cell precursor (BCP) ALL with the aim to replace toxic chemotherapy with better tolerated and more efficacious immunotherapeutic drugs. In standard risk (SR) patients, the CD22 directed antibody-drug conjugate inotuzumab ozogamicin (InO) will be randomly compared with standard of care (SOC) ALL-R3 induction. All patients will receive one SOC consolidation- and one Blina course, compared to historical controls. SR patients with MRD good response will receive 2 additional Blina courses replacing chemotherapy randomly compared with SOC. Patients with high-risk relapse will receive induction investigating InO versus ALL-R3 in an industry-sponsored trial, followed by IntReALL consolidation and allogeneic HSCT. Patients with isolated extramedullary (IEM) relapse are treated based on ALL-REZ BFM 2002 backbone. IntReALL 2020 will establish a federated relapsed/refractory leukaemia board generating personalized recommendations based on clinical, molecular-genetic and drug response profiling data. Patients with very-high risk disease will receive experimental/personalized therapies, including a trial investigating CD19-directed chimeric receptor antigen (CAR) T-cells produced in academic institutions. Other CAR T-cells trials as well as an induction trial for T-ALL relapse will be developed. Documentation and monitoring of the trials and the individualized treatment will be realized using the MARVIN database. Comprehensive statistical and data management activities will warrant the accuracy and interpretability of the data. IntReALL 2020 involves representatives from participating pharmaceutical companies and EMA as well as patient/parent advocates to discuss strategies for developing new drugs within academic trials warranting a benefit for all patients on the results. “This action is part of the Cancer Mission cluster of projects on ‘Diagnosis and treatment’.”

Cancer affects 35,000 children, adolescents and young adults (CAYAC) in Europe each year. Current 5-year survival rates are 80%, but the intensive oncological treatments leave CAYAC Survivors (CAYACS) at increased risk of cancer or treatment-induced late health effects, excess morbidity and mortality, and reduced quality of life (QoL). Follow-up care of survivors includes monitoring of cancers, managing all types of late effects, and maintaining overall health. It should also involve considering the needs of families whose functioning has been disrupted by cancer. There are several challenges providing follow-up care for CAYACS and their families: i) it is resource-demanding in an overburdened healthcare system, ii) psychosocial and supportive care needs are often unmet, and iii) access is inequal between European countries. The overall goal of e-QuoL is to use e-health tools to promote Equity in Quality of Life for CAYACS and their families. It will adapt an existing interoperable personalised e-Health tool that can be used alone or as an add-on module to existing tools such as digital survivorship care plans already used in several European countries. Through participatory research, involving CAYACS, families, associations, networks, health institutes, social sciences and humanities researchers and industrial partners from 15 different countries and backgrounds, we will i) identify the unmet needs of CAYAC families and survivors’ (including vulnerable groups: young age and cognitive impairments) and ii) adapt accessible and affordable tools to address these needs. These tools will provide a person-centred approach from medical follow-up, preventive behaviours (e.g. physical activity, nutrition), psychological and social support (e.g. education, employment) to related health information (e.g. on reproductive issues). Ultimately, e-QuoL will improve CAYACS’ QoL by enabling them to actively engage in their care and better self-manage their health and well-being. This action is part of the Cancer Mission cluster of projects on “Quality of Life.